Landscapes / Targets
FGFR
28 drugs act on FGFR, in 70 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs28
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Approved in China | Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Hepatocellular Carcinoma (HCC), Metastatic Colorectal Cancer and 4 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Biliary Tract Cancer, Advanced or Metastatic Solid Tumor and 15 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | Sep 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Other Solid Tumors, Adult | ||||
| Open drug page | |||||
— |
Approved in China | Dec 2027Phase 3 trial completes | |||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Alveolar Soft Part Sarcoma, Leiomyosarcoma and 6 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Johnson & Johnson (Janssen) · Public JNJ |
Approved | 30 Mar 2028Phase 1/2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Mar 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Urothelial Cancer, Urothelial Carcinoma and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | 31 May 2028Phase 2/3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 May 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Metastatic Pancreatic Cancer | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 25 Feb 2031Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 25 Feb 2031 · Phase 2 trial completes | ||||
| Also tested for | Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Cholangiocarcinoma, Cholangiocarcinoma Metastatic and 5 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 30 Jan 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
Infigratinibnot checked |
Tyrosine kinase inhibitor |
Phase 2/3 | Jan 2027Phase 2/3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Jan 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Achondroplasia, Hypochondroplasia | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2027Phase 2 trial completes | |||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) and 7 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Jun 2028Phase 2/3 trial completes | |||
| Next date | 30 Jun 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Eli Lilly · Public LLY |
Phase 3 | Jul 2028Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Urinary Bladder Neoplasms, Neoplasm Metastasis and 4 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 2 | Nov 2026soonPhase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma and 13 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Jun 2027Phase 2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Liver Cancer, Hepatocellular Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Jun 2027Phase 2 trial completes | |||
| Next date | Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Hepatocellular Carcinoma (HCC) | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Sep 2027Phase 2 trial completes | |||
| Next date | 1 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2027Phase 2 trial completes | |||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Cholangiocarcinoma,Adult | ||||
| Open drug page | |||||
— |
Phase 1/2 | 16 Jun 2028Phase 1/2 trial completes | |||
| Next date | 16 Jun 2028 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 27 of 28 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026